FDA authorizes Pfizer booster shots for seniors, vulnerable

The Food and Drug Administration on Wednesday authorized booster shots of Pfizer’s COVID-19 vaccine for seniors and others who are at high risk for the virus.

The booster shot can only be administered six months after the qualified groups received their second dose of the Pfizer jab.

“Today’s action demonstrates that science and the currently available data continue to guide the FDA’s decision-making for COVID-19 vaccines during this pandemic,” Acting FDA Commissioner Janet Woodcock said in a statement announcing the authorization.

Wednesday’s authorization only applies to the Pfizer vaccine and approval is still needed from the Centers for Disease Control and Prevention before they can be administered.

Under the authorization, adults 65 and older and high-risk groups aged 18 to 64 can get the single dose booster shot if the CDC signs off.

A patient receives his booster dose of Pfizer’s coronavirus vaccine at a county clinic in Southfield, Michigan on August 24, 2021.
Emily Elconin/Getty Images

A CDC advisory panel may vote as early as Thursday on the use of a third shot of the vaccine.

The Biden administration had aimed to roll out booster shots to all Americans aged 16 and older by this week, but an FDA advisory panel last week rejected the broader approval.

The advisory panel said there was not enough evidence to support booster shots for all those aged 16 and sought more safety data.

With Post wires